source
- Experts tout amylin as promising, potentially gentler obesity target as new combo therapies near FDA reviewWhile GLP-1 medicines dominate the weight‑loss market, some observers argue that amylin would have been the logical primary target for obesity treatment a decade ago. Novo Nordisk’s amylin/GLP‑1 c…
- Novartis halts Phase 2 lupus nephritis trial of Fabhalta, cites strategic reasonsNovartis has stopped a Phase 2 study of its complement blocker Fabhalta (iptacopan) in patients with lupus nephritis, a kidney involving form of the disease. The company said the decision was base…